SIGA Technologies
Exchange: NASDAQ
Symbol: SIGA
CEO: Phillip Gomez, Ph.D
HQ: New York, NY

SIGA is a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. SIGA’s lead product is Tecovirimat, also known as ST-246®, an orally administered antiviral drug that targets orthopoxviruses. While Tecovirimat is not yet licensed as safe or effective by the U.S. Food & Drug Administration, it is a novel small-molecule drug that is being delivered to the Strategic Stockpile under Project BioShield.